Topical – Kintor Pharmaceutical is currently developing a new topical treatment for hair loss called GT20029 and has received approval from local authority to proceed with clinical trials. If the trials are successful, GT20029 will be the world’s first topical androgen receptor inhibitor compound that is developed using Kintor’s proprietary Proteolysis Targeting Chimera (PROTAC) platform.

Preclinical studies for GT20029 suggest that this topical formula is superior to other products on the market because it does not cause systemic absorption in our body and hence fewer side effects for the patient while accomplishing the same or higher efficacy as an anti-androgen treatment for hair loss even for male patients.

Click Kintor Pharmaceutical GT20029 trial to become world’s first topical antiandrogen developed for androgenetic alopecia or pattern baldness with promise of efficacy with few side effects to learn more.